GV 2017, L.P. 13D and 13G filings for Verve Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-12-11 4:16 pm Purchase | 2023-12-01 | 13G | Verve Therapeutics, Inc. VERV | GV 2017, L.P. | 12,349,086 15.400% | 1,800,000 (+17.06%) | Filing |
| 2023-02-10 4:05 pm Sale | 2022-12-31 | 13G | Verve Therapeutics, Inc. VERV | GV 2017, L.P. | 10,549,086 17.100% | -424,925 (-3.87%) | Filing |
| 2022-02-14 5:15 pm Purchase | 2021-12-31 | 13G | Verve Therapeutics, Inc. VERV | GV 2017, L.P. | 10,974,011 22.780% | 10,974,011 (New Position) | Filing |